Bluebird Bio's technical breakout following Gilead's acquisition of Kite Pharma could point to more upside ahead.
Biotech stocks jump this week on news of Gilead's $12 billion acquisition of Kite Pharma Inc.
Juno Therapeutics shares continued their rally, but traders will be watching these key levels over the coming days.
A Monday biotech merger triggered a sector-wide advance that could lift junior biotech stocks to multi-year highs.
Momentum stocks can help investors ride a bull market even higher.
Biotech stocks and funds have broken out to 52-week highs and should attract steady buying interest in coming weeks.
Kite Pharma moved sharply lower after reporting a patient death in its 10-Q and the market seems uncertain about where the price is headed.
Amgen aims to expand the use of Blincyto for more indications of acute lymphoblastic leukemia
CTL019 marks Novartis’ first regulatory submission for a CAR-T therapy.
Positive results of its first CAR-T trial for non-Hodgkin's lymphoma spiked Kite's stock 25%